Physician profile
Aristides E Chaconas
NPI 1710954359
$1,442.24
in general payments reported to CMS, 2019-2025
14 companies · $415 in 2025
The $415 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.72 · 2020: $15.83 · 2021: $337 · 2022: $103 · 2023: $145 · 2024: $369 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $900 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $900.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $762.17 | 2019-2025 | Gocovri, Apokyn, Apokyn |
| Sunovion Pharmaceuticals INC. | $139.43 | 2020-2021 | |
| Lilly USA, LLC | $101.18 | 2022-2025 | Amyvid, Kisunla |
| Merz Pharmaceuticals, LLC | $81.12 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $80.88 | 2022-2025 | Crexont |
| Acorda Therapeutics, INC | $57.90 | 2021 | |
| Ge Healthcare | $40.99 | 2021 | |
| Abbvie INC. | $40.84 | 2022-2025 | |
| Avanir Pharmaceuticals, INC. | $33.70 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $28.24 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $24.11 | 2021 | |
| Kyowa Kirin, INC. | $18.90 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.34 | 2019 | |
| Lundbeck LLC | $14.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aristides Chaconas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.